Searched for
SOLOSEC
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Use this ratio both in bullish and volatile markets. 6 stocks that fit the bill with upside potential of up to 37%Looking only at the PE ratio creates more than one problem. For one, it creates an issue in terms of buying based on PE; secondly, just bec...
- Lupin divests women's health specialty business in US to Evofem Biosciences for nearly $84 mnLupin announced the sale of its US commercial women’s health specialty business, focusing on Solosec, to Evofem Biosciences. Solosec, an FD...
- Lupin gets USFDA nod for using specialty drug Solosec on adolescentsThe supplemental adolescent approval enhances Solosec's strong position as the first and only single-dose oral prescription antimicrobial a...
- Lupin partners with Exeltis for marketing its specialty drug Solosec in USET reported in October about Lupin trying to find a marketing partner or even be open to the idea of possible sale of its key specialty dru...
- Lupin skids as failed USFDA specifications lead to recalls of 2 drugsThe company’s scrip fell to a low of Rs 937.15 as against Rs 951.80 at previous close on the National Stock Exchange.
- Lupin says trying to find marketing partner, or open to possible sale of specialty drug SolosecIndian drug makers like Lupin, Dr Reddy's, Sun Pharma, among others have placed bets on specialty drugs that are protected by patents as st...
- Lupin Q2 results: Firms posts Rs 2,095 crore loss due to one-off impairmentsDuring the quarter, the company booked a provision of Rs 1879.6 crore towards litigation and settlement related to diabetic drug Glumetza c...
- Lupin arm gets supplemental new drug application approval from US regulator for SolosecThe drug was approved in the US in 2017 for the treatment of bacterial vaginosis in adult women, the company said.
- CLSA retains sell on Lupin, lowers target price to Rs 640The brokerage has cut earnings estimate on Lupin by 2-4%, factoring in lower US revenues due to slow ramp-up of Solosec and weak launch pip...
- Lupin aims to launch new products across geographies this fiscal"Looking ahead, FY2020 is an exciting year for Lupin as we plan to bring our first biosimilar to market," company said.
- Lupin gains 3% on Credit Suisse upgrade, Nomura’s buy ratingNomura has maintained a ‘buy’ rating on Lupin with a target price of Rs 1,017.
- Reduce Lupin, target Rs 840: Kotak Institutional EquitiesReduce Lupin at a price target of Rs 840.
- Buy Lupin, target Rs 985: HDFC SecuritiesBuy Lupin at a price target of Rs 985.
- Lupin still on track to meet $800-million FY19 sales target: Ramesh SwaminathanThings not as bad as they were in the past and should be looking better, says Lupin CFO.
- For every rupee depreciation, we expect to add Rs 40 cr to bottom line: Ramesh Swaminathan, Lupin“Between 25% and 30% of our total exposures are hedged.”
- Complex generics, biosimilars & specialty to be growth drivers: LupinWhile sustaining and growing its presence in the generics segment, Lupin is planning to invest heavily in developing high barrier products ...
- Lupin hire Nicholas Hart to head US businessHis past experiences include Business Unit Head for Reproductive Health at Ferring Pharmaceuticals, Inc and Senior Vice President of Sales ...
- Lupin makes impairment provision for GavisLupin took a hit worth Rs 1,464.35 crore on US-based Gavis, which it acquired in 2015 for $880 million (Rs 5,610 crore then).
- Lupin's US arm takes over Symbiomix TherapeuticsLupin had entered into an arrangement to acquire the company earlier this year.
Load More
